- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Sandoz Group
Market Cap: CHF 21.4b
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
SDZ
CHF 49.76
7D
2.8%
1Y
29.7%
Galderma Group
Market Cap: CHF 33.7b
Operates as a dermatology company worldwide.
GALD
CHF 142.10
7D
3.8%
1Y
75.3%
Lonza Group
Market Cap: CHF 41.2b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 586.60
7D
6.0%
1Y
5.5%
Roche Holding
Market Cap: CHF 232.7b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 271.20
7D
-4.4%
1Y
-3.6%